Lenalidomide Mercury Pharmaceuticals

Lenalidomide, the active ingredient in Lenalidomide Mercury Pharmaceuticals, is an immunomodulatory agent (IMiD) presented as an oral tablet for oral use. It is employed in the treatment of certain blood cancers, including multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma, in adult patients.

GNH USA supplies Lenalidomide Mercury Pharmaceuticals as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies, and clinics worldwide, providing reliable access to quality‑assured medication for oncologic care and supporting therapeutic programs across regions.

Lenalidomide is used in hematologic malignancies and related myelodysplastic conditions. - Multiple myeloma: improves progression‑free survival and overall response rates in adult patients. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission. - Mantle cell lymphoma: provides therapeutic benefit in relapsed or refractory disease.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: lowered neutrophil count increasing infection risk. - Thrombocytopenia: reduced platelet count leading to bleeding tendency. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require hydration. - Rash: mild skin eruptions. - Nausea: upset stomach and urge to vomit. - Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly low neutrophils with fever. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: elevated liver enzymes or liver injury. - Hypersensitivity reactions: including Stevens‑Johnson syndrome.

When prescribing Lenalidomide, clinicians should observe several precautions to minimize risks. - Pregnancy contraindication: drug is teratogenic and must not be used in pregnancy. - Contraception requirement: both male and female patients of reproductive potential must use effective contraception during treatment and for at least four weeks after the last dose. - Thromboembolic risk: assess need for prophylactic anticoagulation, especially when combined with dexamethasone or other agents. - Renal function: dose adjustment may be needed in patients with impaired renal clearance. - Hematologic monitoring: regular complete blood counts are required to detect neutropenia or thrombocytopenia. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Lenalidomide interacts with several medicines; awareness of these interactions helps avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly decrease lenalidomide exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): increased risk of bleeding when combined with lenalidomide.

Moderate Interactions (Monitor Closely): - P-glycoprotein inhibitors (e.g., verapamil, quinidine): may raise plasma levels of lenalidomide. - Immunosuppressants (e.g., cyclosporine, tacrolimus): may enhance immunomodulatory effects and infection risk. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may modestly increase lenalidomide concentrations.